Discontinued — last reported Q4 '25
Products & Services · Unfunded R&D commitment
Litifilimab — Unfunded R&D commitment
Royalty Pharma Litifilimab — Unfunded R&D commitment decreased by 50.0% to $50M in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ4 2025Feb 11, 2026
How to read this metric
A decrease suggests the asset is moving closer to commercialization, while an increase may indicate extended clinical trials or expanded development scope.
Detailed definition
This metric tracks the specific portion of the firm's total unfunded commitments that is strictly earmarked for research...
Peer comparison
Similar to R&D funding obligations or committed clinical trial support payments in biopharma development agreements.
Metric ID:
rprx_segment_litifilimab_unfunded_r_d_commitmentHistorical Data
4 periods
| Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | $200M | $150M | $100M | $50M |
| QoQ Change | — | -25.0% | -33.3% | -50.0% |
Range$50M – $200M
Current Streak3+ quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's litifilimab — unfunded r&d commitment?
- Royalty Pharma (RPRX) reported litifilimab — unfunded r&d commitment of $50M in Q4 2025.
- What does litifilimab — unfunded r&d commitment mean?
- The remaining amount of money the company is obligated to pay specifically for Litifilimab's research and development.